Publications
121 results found
Agarwal R, Alifrangis C, Everard J, et al., 2014, Management and Survival of Patients with FIGO High-risk Gestational Trophoblastic Neoplasia, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 59, Pages: 7-12, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 25
Agarwal R, Alifrangis C, Everard J, et al., 2014, Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010., J Reprod Med, Vol: 59, Pages: 7-12, ISSN: 0024-7758
OBJECTIVE: To present survival rates of high-risk gestational trophoblastic neoplasia (GTN) (FIGO score > 7) patients treated between 1995 and 2010 in the U.K. Death due to GTN is largely confined to patients with high-risk disease. In the U.K. a national system ensures that all patients are treated at only 2 specialist centers: Charing Cross Hospital (CXH) in London and Weston Park Hospital (WPH) in Sheffield. STUDY DESIGN: A total of 196 high-risk patients were identified using the CXH and WPH GTN databases, based on the risk score at the time of presentation. RESULTS: In all, 140 CXH and 56 WPH high-risk patients were treated with EMA/CO (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) and MEA (methotrexate, etoposide, actinomycin D), respectively. The FIGO score at presentation ranged from 6-23. Eight patients (7from WPH and 1 from CXH) who were treated prior to 2002 as high-risk based on their pre-2002 scoring scored a 6 using FIGO 2002. Two (1%) patients died within 4 weeks of starting treatment (early death), 12 (6%) relapsed, and 9 patients subsequently died due to drug resistance. The overall survival was 94%, with a median follow-up of 4.69 years. CONCLUSION: In the context of a national trophoblastic disease service, patients with high-risk GTN have an excellent prognosis with EMA/CO or MEA.
Bolze P-A, Weber B, Fisher RA, et al., 2013, First confirmation by genotyping of transplacental choriocarcinoma transmission, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, Vol: 209, Pages: E4-E6, ISSN: 0002-9378
- Author Web Link
- Cite
- Citations: 7
Seckl MJ, Sebire NJ, Fisher RA, et al., 2013, Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, Vol: 24, Pages: 39-50, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 231
Reddy R, Akoury E, Ngoc MPN, et al., 2013, Report of four new patients with protein-truncating mutations in <i>C6orf221</i>/<i>KHDC3L</i> and colocalization with <i>NLRP7</i>, EUROPEAN JOURNAL OF HUMAN GENETICS, Vol: 21, Pages: 957-964, ISSN: 1018-4813
- Author Web Link
- Cite
- Citations: 53
Sita-Lumsden A, Medani H, Fisher R, et al., 2013, Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6, BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 120, Pages: 1012-1015, ISSN: 1470-0328
- Author Web Link
- Cite
- Citations: 25
Savage P, Sebire N, Dalton T, et al., 2013, Partial molar pregnancy after intracytoplasmic sperm injection occurring as a result of diploid sperm usage, JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, Vol: 30, Pages: 761-764, ISSN: 1058-0468
- Author Web Link
- Cite
- Citations: 10
Savage PM, Sita-Lumsden A, Dickson S, et al., 2013, The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome, JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 33, Pages: 406-411, ISSN: 0144-3615
- Author Web Link
- Cite
- Citations: 61
Fallahian M, Sebire NJ, Savage PM, et al., 2013, Mutations in NLRP7 and KHDC3L Confer a Complete Hydatidiform Mole Phenotype on Digynic Triploid Conceptions, HUMAN MUTATION, Vol: 34, Pages: 301-308, ISSN: 1059-7794
- Author Web Link
- Cite
- Citations: 41
Alifrangis C, Agarwal R, Short D, et al., 2013, EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis, JOURNAL OF CLINICAL ONCOLOGY, Vol: 31, Pages: 280-286, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 135
Sebire NJ, Savage PM, Seckl MJ, et al., 2013, Histopathological features of biparental complete hydatidiform moles in women with <i>NLRP7</i> mutations, PLACENTA, Vol: 34, Pages: 50-56, ISSN: 0143-4004
- Author Web Link
- Cite
- Citations: 32
Agarwal R, Harding V, Short D, et al., 2012, Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia, British Journal of Cancer, Vol: 106, Pages: 1089-1094, ISSN: 0007-0920
Background:Neo-angiogenesis is a hallmark of cancer. The aim of this study was to test the hypothesis, in a prospective patient cohort, that in low-risk gestational trophoblastic neoplasia (LR-GTN) the uterine artery pulsatility index (UAPI), a measure of tumour vascularity, can predict resistance to methotrexate chemotherapy (MTX-R).Methods:286 LR-GTN patients (Charing Cross Hospital (CXH) score 0–8, or FIGO score 0–6) were treated with methotrexate between January 2008 and June 2011 at CXH. During staging investigations, patients underwent a Doppler ultrasound to assess the UAPI.Results:239 patients were assessable for both UAPI and MTX-R. The median UAPI was lower (higher vascularity) in MTX-R compared with MTX-sensitive patients (0.8 vs 1.4, P<0.0001). In multivariate logistic regression, UAPI⩽1 predicted MTX-R, independent of both CXH and FIGO scores. The risk of MTX-R in patients with a FIGO score of 6 and UAPI⩽1 was 100% vs 20% in patients with UAPI>1 (χ2 P<0.0001).Conclusion:UAPI represents an independently validated clinically useful predictor of MTX-R in LR-GTN. Further, consideration of whether to incorporate UAPI into the FIGO scoring system is now warranted so that patients with a score of 6 and a UAPI ⩽1 might be upstaged and offered combination chemotherapy rather than MTX.
Yang VS, Carter SA, Ng Y, et al., 2012, Distinct activities of the anaphase-promoting complex/cyclosome (APC/C) in mouse embryonic cells, CELL CYCLE, Vol: 11, Pages: 846-855, ISSN: 1538-4101
- Author Web Link
- Cite
- Citations: 8
Dixon PH, Trongwongsa P, Abu-Hayyah S, et al., 2012, Mutations in <i>NLRP7</i> are associated with diploid biparental hydatidiform moles, but not androgenetic complete moles, JOURNAL OF MEDICAL GENETICS, Vol: 49, Pages: 206-211, ISSN: 0022-2593
- Author Web Link
- Cite
- Citations: 33
Fisher RA, Sebire NJ, 2012, Hydatidiform Mole, Brenner's Online Encyclopedia of Genetics, Editors: Maloy, Hughes
Fisher RA, Lavery SA, Carby A, et al., 2011, What a difference an egg makes, LANCET, Vol: 378, Pages: 1974-1974, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 35
Lasecka L, Dixon PH, Molokhia M, et al., 2011, 667C>T and 1298A>C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia, GYNECOLOGIC ONCOLOGY, Vol: 123, Pages: 605-609, ISSN: 0090-8258
- Author Web Link
- Cite
- Citations: 6
Parry DA, Logan CV, Hayward BE, et al., 2011, Mutations Causing Familial Biparental Hydatidiform Mole Implicate <i>C6orf221</i> as a Possible Regulator of Genomic Imprinting in the Human Oocyte, AMERICAN JOURNAL OF HUMAN GENETICS, Vol: 89, Pages: 451-458, ISSN: 0002-9297
- Author Web Link
- Cite
- Citations: 168
Tolhurst RS, Thomas RS, Kyle FJ, et al., 2011, Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth, BREAST CANCER RESEARCH AND TREATMENT, Vol: 128, Pages: 357-368, ISSN: 0167-6806
- Author Web Link
- Cite
- Citations: 21
Buyukkurt S, Fisher RA, Vardar MA, et al., 2010, Heterogeneity in recurrent complete hydatidiform mole: Presentation of two new Turkish families with different genetic characteristics, PLACENTA, Vol: 31, Pages: 1023-1025, ISSN: 0143-4004
- Author Web Link
- Cite
- Citations: 16
Fisher RA, 2010, Familial Recurrent Hydatidiform Moles, 2nd National Seminar on Gestational Trophoblastic Disease
Fisher RA, 2010, Genetic Diagnosis of Gestational Trophoblastic Disease, 2nd National Seminar on Gestational Trophoblastic Disease
Fisher RA, 2009, Genetics of Hydatidiform Moles, XV World Congress on Gestational Trophoblastic Diseases
Wang CM, Dixon PH, Decordova S, et al., 2009, Identification of 13 novel <i>NLRP7</i> mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region, JOURNAL OF MEDICAL GENETICS, Vol: 46, Pages: 569-575, ISSN: 0022-2593
- Author Web Link
- Cite
- Citations: 110
Sebire NJ, Lindsay I, Fisher RA, et al., 2009, Intraplacental choriocarcinoma: Experience from a tertiary referral center and relationship with infantile choriocarcinoma, FETAL AND PEDIATRIC PATHOLOGY, Vol: 24, Pages: 21-29, ISSN: 1551-3815
- Author Web Link
- Cite
- Citations: 39
Schmid P, Nagai Y, Agarwal R, et al., 2009, Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study, LANCET, Vol: 374, Pages: 48-55, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 157
Patten DK, Lindsay I, Fisher R, et al., 2008, Gestational Choriocarcinoma Mimicking a Uterine Adenocarcinoma, JOURNAL OF CLINICAL ONCOLOGY, Vol: 26, Pages: 5126-5127, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 6
Sebire NJ, Fisher RA, Williams S, et al., 2008, Indoleamine 2,3-Dioxygenase Expression in Gestational Trophoblastic Disease Implications for Development of Immunotherapeutic Approaches, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 53, Pages: 789-792, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 3
Fisher RA, 2008, Familial Recurrent Hydatidiform Moles, Contemporary Trends in Gynecological Oncology Meeting
Fisher RA, 2008, Genetics of Gestational Trophoblastic Disease, Contemporary Trends in Gynecological Oncology Meeting
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.